annual CFF:
-$6.04B+$979.22M(+13.95%)Summary
- As of today (May 21, 2025), GSK annual cash flow from financing activities is -$6.04 billion, with the most recent change of +$979.22 million (+13.95%) on December 31, 2024.
- During the last 3 years, GSK annual CFF has risen by +$4.40 billion (+42.15%).
- GSK annual CFF is now -204.67% below its all-time high of $5.77 billion, reached on December 31, 1995.
Performance
GSK Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$1.08B+$2.07B(+209.56%)Summary
- As of today (May 21, 2025), GSK quarterly cash flow from financing activities is $1.08 billion, with the most recent change of +$2.07 billion (+209.56%) on March 31, 2025.
- Over the past year, GSK quarterly CFF has increased by +$2.42 billion (+180.35%).
- GSK quarterly CFF is now -89.90% below its all-time high of $10.70 billion, reached on March 31, 2022.
Performance
GSK quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$3.62B+$2.42B(+40.15%)Summary
- As of today (May 21, 2025), GSK TTM cash flow from financing activities is -$3.62 billion, with the most recent change of +$2.42 billion (+40.15%) on March 31, 2025.
- Over the past year, GSK TTM CFF has increased by +$4.36 billion (+54.68%).
- GSK TTM CFF is now -267.88% below its all-time high of $2.15 billion, reached on March 31, 2022.
Performance
GSK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
GSK Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.9% | +180.3% | +54.7% |
| 3 y3 years | +42.1% | -89.9% | -267.9% |
| 5 y5 years | -157.1% | +180.1% | +57.3% |
GSK Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -692.6% | +42.1% | -89.9% | +117.1% | -267.9% | +64.1% |
| 5 y | 5-year | -692.6% | +53.5% | -89.9% | +117.1% | -267.9% | +73.7% |
| alltime | all time | -204.7% | +53.5% | -89.9% | +117.1% | -267.9% | +73.7% |
GSK Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $1.08B(-209.6%) | -$3.62B(-40.1%) |
| Dec 2024 | -$6.04B(-14.0%) | -$986.04M(-42.6%) | -$6.04B(-36.3%) |
| Sep 2024 | - | -$1.72B(-13.7%) | -$9.48B(-5.2%) |
| Jun 2024 | - | -$1.99B(+48.1%) | -$10.00B(+25.3%) |
| Mar 2024 | - | -$1.34B(-69.6%) | -$7.98B(+13.6%) |
| Dec 2023 | -$7.02B(-788.7%) | -$4.42B(+97.9%) | -$7.02B(+70.4%) |
| Sep 2023 | - | -$2.24B(-8288.3%) | -$4.12B(+10.6%) |
| Jun 2023 | - | $27.30M(-107.1%) | -$3.72B(-63.0%) |
| Mar 2023 | - | -$386.53M(-74.6%) | -$10.06B(-1087.5%) |
| Dec 2022 | $1.02B(-109.8%) | -$1.52B(-17.2%) | $1.02B(-181.0%) |
| Sep 2022 | - | -$1.84B(-70.8%) | -$1.26B(-1.3%) |
| Jun 2022 | - | -$6.31B(-159.0%) | -$1.28B(-159.2%) |
| Mar 2022 | - | $10.70B(-381.4%) | $2.15B(-120.6%) |
| Dec 2021 | -$10.44B(-19.7%) | -$3.80B(+104.7%) | -$10.44B(+11.5%) |
| Sep 2021 | - | -$1.86B(-35.6%) | -$9.36B(-29.2%) |
| Jun 2021 | - | -$2.88B(+52.1%) | -$13.22B(-2.4%) |
| Mar 2021 | - | -$1.90B(-30.3%) | -$13.55B(+4.2%) |
| Dec 2020 | -$13.00B(+453.5%) | -$2.72B(-52.4%) | -$13.00B(-5.5%) |
| Sep 2020 | - | -$5.72B(+77.8%) | -$13.76B(+31.4%) |
| Jun 2020 | - | -$3.22B(+138.5%) | -$10.47B(+23.7%) |
| Mar 2020 | - | -$1.35B(-61.3%) | -$8.47B(+260.4%) |
| Dec 2019 | -$2.35B(-72.4%) | -$3.48B(+43.5%) | -$2.35B(-28.8%) |
| Sep 2019 | - | -$2.43B(+100.4%) | -$3.30B(+11.5%) |
| Jun 2019 | - | -$1.21B(-125.4%) | -$2.96B(-12.0%) |
| Mar 2019 | - | $4.77B(-207.7%) | -$3.36B(-60.6%) |
| Dec 2018 | -$8.52B(+3.5%) | -$4.43B(+112.3%) | -$8.52B(+3.4%) |
| Sep 2018 | - | -$2.09B(+29.3%) | -$8.24B(+16.4%) |
| Jun 2018 | - | -$1.61B(+310.1%) | -$7.08B(+4.7%) |
| Mar 2018 | - | -$393.51M(-90.5%) | -$6.76B(-17.9%) |
| Dec 2017 | -$8.24B(-4.9%) | -$4.15B(+348.4%) | -$8.24B(+19.3%) |
| Sep 2017 | - | -$925.52M(-28.5%) | -$6.90B(-16.4%) |
| Jun 2017 | - | -$1.29B(-30.8%) | -$8.26B(-4.6%) |
| Mar 2017 | - | -$1.87B(-33.6%) | -$8.65B(-0.1%) |
| Dec 2016 | -$8.66B(-20.2%) | -$2.82B(+23.8%) | -$8.66B(+20.5%) |
| Sep 2016 | - | -$2.28B(+34.8%) | -$7.19B(-11.3%) |
| Jun 2016 | - | -$1.69B(-10.2%) | -$8.11B(-19.2%) |
| Mar 2016 | - | -$1.88B(+39.7%) | -$10.03B(-7.6%) |
| Dec 2015 | -$10.86B(+22.3%) | -$1.35B(-57.9%) | -$10.86B(-10.8%) |
| Sep 2015 | - | -$3.20B(-11.5%) | -$12.17B(+31.9%) |
| Jun 2015 | - | -$3.61B(+33.8%) | -$9.23B(+26.5%) |
| Mar 2015 | - | -$2.70B(+1.5%) | -$7.29B(-17.8%) |
| Dec 2014 | -$8.88B(-9.6%) | -$2.66B(+950.8%) | -$8.88B(+0.8%) |
| Sep 2014 | - | -$253.37M(-84.9%) | -$8.81B(-14.6%) |
| Jun 2014 | - | -$1.68B(-60.9%) | -$10.32B(-12.8%) |
| Mar 2014 | - | -$4.28B(+65.1%) | -$11.84B(+20.6%) |
| Dec 2013 | -$9.81B(+84.8%) | -$2.59B(+47.2%) | -$9.81B(+11.2%) |
| Sep 2013 | - | -$1.76B(-44.9%) | -$8.82B(-1.6%) |
| Jun 2013 | - | -$3.20B(+41.5%) | -$8.97B(+59.8%) |
| Mar 2013 | - | -$2.26B(+41.0%) | -$5.61B(+5.7%) |
| Dec 2012 | -$5.31B(-46.9%) | -$1.60B(-16.1%) | -$5.31B(-7.6%) |
| Sep 2012 | - | -$1.91B(-1302.0%) | -$5.75B(-15.0%) |
| Jun 2012 | - | $158.84M(-108.1%) | -$6.76B(-31.4%) |
| Mar 2012 | - | -$1.96B(-4.0%) | -$9.85B(-1.4%) |
| Dec 2011 | -$9.99B | -$2.04B(-30.2%) | -$9.99B(+5.3%) |
| Sep 2011 | - | -$2.92B(-0.4%) | -$9.49B(+16.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2011 | - | -$2.93B(+39.7%) | -$8.15B(-0.2%) |
| Mar 2011 | - | -$2.10B(+36.5%) | -$8.17B(-4.9%) |
| Dec 2010 | -$8.59B(+97.7%) | -$1.54B(-2.4%) | -$8.59B(-4.3%) |
| Sep 2010 | - | -$1.58B(-46.6%) | -$8.97B(+63.7%) |
| Jun 2010 | - | -$2.95B(+17.1%) | -$5.48B(-7.5%) |
| Mar 2010 | - | -$2.52B(+31.2%) | -$5.93B(+36.4%) |
| Dec 2009 | -$4.35B(-52.1%) | -$1.92B(-200.3%) | -$4.35B(-14.8%) |
| Sep 2009 | - | $1.92B(-156.4%) | -$5.10B(-51.9%) |
| Jun 2009 | - | -$3.40B(+261.6%) | -$10.61B(+137.9%) |
| Mar 2009 | - | -$939.94M(-64.9%) | -$4.46B(-50.9%) |
| Dec 2008 | -$9.08B(+160.3%) | -$2.68B(-25.3%) | -$9.08B(+170.4%) |
| Sep 2008 | - | -$3.59B(-230.5%) | -$3.36B(+12.0%) |
| Jun 2008 | - | $2.75B(-149.5%) | -$3.00B(-61.4%) |
| Mar 2008 | - | -$5.56B(-282.8%) | -$7.77B(+122.7%) |
| Dec 2007 | -$3.49B(-60.5%) | $3.04B(-194.2%) | -$3.49B(-60.4%) |
| Sep 2007 | - | -$3.23B(+59.7%) | -$8.81B(+24.1%) |
| Jun 2007 | - | -$2.02B(+58.2%) | -$7.10B(-13.5%) |
| Mar 2007 | - | -$1.28B(-44.0%) | -$8.21B(-7.1%) |
| Dec 2006 | -$8.83B(+66.6%) | -$2.28B(+50.1%) | -$8.83B(+3.2%) |
| Sep 2006 | - | -$1.52B(-51.4%) | -$8.56B(-15.7%) |
| Jun 2006 | - | -$3.13B(+64.4%) | -$10.15B(+100.5%) |
| Mar 2006 | - | -$1.90B(-5.1%) | -$5.06B(-4.5%) |
| Dec 2005 | -$5.30B(-15.1%) | -$2.01B(-35.6%) | -$5.30B(+30.8%) |
| Sep 2005 | - | -$3.11B(-258.9%) | -$4.05B(-35.1%) |
| Jun 2005 | - | $1.96B(-191.6%) | -$6.25B(+5.0%) |
| Mar 2005 | - | -$2.14B(+182.4%) | -$5.95B(-4.7%) |
| Dec 2004 | -$6.24B(-3.1%) | -$757.90M(-85.7%) | -$6.24B(-42.2%) |
| Sep 2004 | - | -$5.31B(-334.9%) | -$10.80B(+78.1%) |
| Jun 2004 | - | $2.26B(-192.9%) | -$6.06B(-21.9%) |
| Mar 2004 | - | -$2.43B(-54.2%) | -$7.76B(+20.4%) |
| Dec 2003 | -$6.44B(+173.6%) | -$5.31B(+824.8%) | -$6.44B(+1158.7%) |
| Sep 2003 | - | -$574.53M(-202.4%) | -$511.92M(-22.6%) |
| Jun 2003 | - | $561.26M(-150.3%) | -$661.45M(-75.7%) |
| Mar 2003 | - | -$1.12B(-280.7%) | -$2.72B(+15.4%) |
| Dec 2002 | -$2.35B(-41.2%) | $618.24M(-185.4%) | -$2.35B(-65.0%) |
| Sep 2002 | - | -$724.05M(-51.6%) | -$6.73B(+15.6%) |
| Jun 2002 | - | -$1.49B(+98.1%) | -$5.82B(+37.1%) |
| Mar 2002 | - | -$754.53M(-79.9%) | -$4.25B(+6.0%) |
| Dec 2001 | -$4.01B(+384.0%) | -$3.76B(-2150.4%) | -$4.01B(+271.7%) |
| Sep 2001 | - | $183.17M(+123.4%) | -$1.08B(-15.7%) |
| Jun 2001 | - | $82.00M(-115.9%) | -$1.28B(-8.7%) |
| Mar 2001 | - | -$515.40M(-37.7%) | -$1.40B(+69.1%) |
| Dec 2000 | -$827.58M(-246.1%) | -$827.58M(+4812.2%) | -$827.58M(<-9900.0%) |
| Sep 2000 | - | -$16.85M(-57.2%) | $100.00(-100.0%) |
| Jun 2000 | - | -$39.35M(-170.0%) | $16.85M(-70.0%) |
| Mar 2000 | - | $56.19M | $56.19M |
| Dec 1999 | $566.34M(+0.8%) | - | - |
| Dec 1998 | $561.86M(-681.3%) | - | - |
| Dec 1997 | -$96.66M(-90.6%) | - | - |
| Dec 1996 | -$1.03B(-117.8%) | - | - |
| Dec 1995 | $5.77B(+67.4%) | - | - |
| Jun 1995 | $3.45B(+5807.0%) | - | - |
| Jun 1994 | $58.37M(-62.6%) | - | - |
| Jun 1993 | $156.04M(-119.0%) | - | - |
| Jun 1992 | -$819.74M(-193.4%) | - | - |
| Jun 1991 | $877.65M | - | - |
FAQ
- What is GSK annual cash flow from financing activities?
- What is the all time high annual CFF for GSK?
- What is GSK annual CFF year-on-year change?
- What is GSK quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for GSK?
- What is GSK quarterly CFF year-on-year change?
- What is GSK TTM cash flow from financing activities?
- What is the all time high TTM CFF for GSK?
- What is GSK TTM CFF year-on-year change?
What is GSK annual cash flow from financing activities?
The current annual CFF of GSK is -$6.04B
What is the all time high annual CFF for GSK?
GSK all-time high annual cash flow from financing activities is $5.77B
What is GSK annual CFF year-on-year change?
Over the past year, GSK annual cash flow from financing activities has changed by +$979.22M (+13.95%)
What is GSK quarterly cash flow from financing activities?
The current quarterly CFF of GSK is $1.08B
What is the all time high quarterly CFF for GSK?
GSK all-time high quarterly cash flow from financing activities is $10.70B
What is GSK quarterly CFF year-on-year change?
Over the past year, GSK quarterly cash flow from financing activities has changed by +$2.42B (+180.35%)
What is GSK TTM cash flow from financing activities?
The current TTM CFF of GSK is -$3.62B
What is the all time high TTM CFF for GSK?
GSK all-time high TTM cash flow from financing activities is $2.15B
What is GSK TTM CFF year-on-year change?
Over the past year, GSK TTM cash flow from financing activities has changed by +$4.36B (+54.68%)